Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2022-09-02 Regulatory Filings
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
풍문또는보도에대한해명(확정)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding a 'Clarification of Rumors or Reports' (풍문 또는 보도에 대한 해명). It addresses specific media speculation about a company's business activities (vaccine development) and provides a definitive update on the status of those negotiations. Since this is a standard regulatory disclosure for public companies in Korea to address market rumors and does not fit into specific categories like M&A or financial reports, it falls under the general regulatory filing category.
2022-09-02 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Samchundang Pharm Co., Ltd. for the period of January 1, 2022, to June 30, 2022. It contains comprehensive financial data, business operations, management discussion, and detailed financial statements, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-16 Korean
풍문또는보도에대한해명(미확정)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding a 'Clarification of Rumors or Reports' (풍문 또는 보도에 대한 해명). It addresses specific media reports about the company's business activities and provides a status update on ongoing negotiations. Since this is a general regulatory disclosure regarding corporate rumors and does not fit into specific categories like M&A, financial reports, or board changes, it is classified as a general Regulatory Filing (RNS).
2022-08-03 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-deal Roadshow) for Samchundang Pharm. It provides details such as the date, location (conference call), purpose, and instructions on where to access the IR materials. Since it is an announcement of an event and the availability of materials rather than the presentation itself, it falls under the category of a regulatory filing announcement.
2022-07-01 Korean
풍문또는보도에대한해명(미확정)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding a 'Clarification of Rumors or Reports' (풍문 또는 보도에 대한 해명). It addresses specific media reports about the company's business activities and provides a status update (undetermined/in progress). Since this is a standard regulatory disclosure requirement for listed companies in Korea to address market rumors, and it does not fit into specific categories like M&A or financial reports, it is classified as a general Regulatory Filing (RNS).
2022-06-03 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Samchundang Pharm Co., Ltd. for the period of January 1, 2022, to March 31, 2022. It contains detailed financial information, business operations, management discussion, and consolidated financial statements, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.